Middle cerebral artery remodeling following transient brain ischemia is linked to early postischemic hyperemia: A target of uric acid treatment

Yara Onetti,1 Ana P. Dantas,2 Belén Pérez,1 Roger Cugota,1 Angel Chamorro,3 Anna M. Planas,4 Elisabet Vila,1* and Francesc Jiménez-Altayó1*  
1Facultat de Medicina, Departament de Farmacologia, Terapèutica i Toxicologia, Institut de Neurociències, Universitat Autònoma de Barcelona, Bellaterra, Spain; 2Institut Clinic del Tórax, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain; 3Functional Unit of Cerebrovascular Diseases, Hospital Clinic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain; and 4Departament d’Isquèmia Cerebral i Neurodegeneració, Institut de Recerca Biomèdica, Consejo Superior de Investigaciones Científicas, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain

Submitted 2 January 2015; accepted in final form 28 January 2015

Onetti Y, Dantas AP, Pérez B, Cugota R, Chamorro A, Planas AM, Vila E, Jiménez-Altayó F. Middle cerebral artery remodeling following transient brain ischemia is linked to early postischemic hyperemia: A target of uric acid treatment. Am J Physiol Heart Circ Physiol 308: H862–H874, 2015. First published January 30, 2015; doi:10.1152/ajpheart.00001.2015.—Ischemia impairs blood supply to the brain, and reperfusion is important to restore cerebral blood flow (CBF) and rescue neurons from cell death. However, reperfusion can induce CBF values exceeding the basal values before ischemia. This hyperemic effect has been associated with a worse ischemic brain damage, albeit the mechanisms that contribute to infarct expansion are not clear. In this study, we investigated the influence of early postischemic hyperemia on brain damage and middle cerebral artery (MCA) properties and the effect of treatment with the endogenous antioxidant uric acid (UA). The MCA was occluded for 90 min followed by 24 h reperfusion in adult male Sprague-Dawley rats. Cortical CBF increases at reperfusion beyond 20% of basal values were taken as indicative of hyperemia. UA (16 mg/kg) or vehicle (Locke’s buffer) was administered intravenously 135 min after MCA occlusion. Hyperemic compared with nonhyperemic rats showed MCA wall thickening (sham: 22.4 ± 0.8 μm; nonhyperemic: 23.1 ± 1.2 μm; hyperemic: 27.8 ± 0.9 at 60 mmHg; P < 0.001, hyperemic vs. sham) involving adventitial cell proliferation, increased oxidative stress, and interleukin-18, and more severe brain damage. Thus MCA remodeling after ischemia-reperfusion takes place under vascular oxidative and inflammatory stress conditions linked to hyperemia. UA administration attenuated MCA wall thickening, induced passive lumen expansion, and reduced brain damage in hyperemic rats, although it did not increase brain UA concentration. We conclude that hyperemia at reperfusion following brain ischemia induces vascular damage that can be attenuated by administration of the endogenous antioxidant UA.

ischemia-reperfusion; oxidative stress; peroxynitrite; interleukin-18; macrophages

REPERFUSION AFTER BRAIN ISCHEMIA is important to restore the blood supply to the brain tissue. Thrombolysis with recombinant tissue plasminogen activator (rtPA) is currently the only approved treatment for ischemic stroke but carries some risks such as hemorrhagic transformation (38). Reperfusion injury is a complex phenomenon attributed to multiple damaging pro-

cesses, and it could be an important target in stroke therapy. Following experimental brain ischemia, reperfusion can induce cerebral blood flow (CBF) increases above basal levels (33, 34, 35), a process called reactive hyperemia. Reactive hyperemia is not restricted to animals, since there is evidence that some patients can develop hyperperfusion shortly after thrombolysis with rtPA (16). Hyperemia at reperfusion was associated with the worst brain injury in pioneer studies of experimental brain ischemia (33). In a more recent study, rats that developed cortical hyperemia immediately after reperfusion showed larger cortical infarcts and worse neurological deficits than rats not showing hyperemia (23). Therefore, it is suggested that reactive hyperemia at early reperfusion could be a sign of reperfusion injury and also a potential target for therapeutic intervention.

During cerebral ischemia, and particularly at reperfusion, there is a surge of oxidative stress in the brain (29). Certain antioxidants have shown protective effects in preclinical studies of ischemia-reperfusion (I/R), indicating a key role for oxidative stress in brain injury after I/R (27). NO can react with superoxide anion (O2·−) generated at reperfusion to form the potentially harmful molecule peroxynitrite (ONOO−), leading to tissue damage (4). Hyperemic rats show comparatively more brain protein nitrotyrosination that may contribute to the worse outcome (23).

Uric acid (UA) is a powerful endogenous antioxidant that has shown protective effects against ischemic brain damage (1). Several studies provided evidence that exogenously administered UA is neuroprotective in animal models of transient focal brain ischemia (18, 28, 39). The observed neuroprotective effects of UA have led to a multicentric Phase III clinical trial (URICO-ICTUS) to analyze if UA administration increases the clinical benefits of rtPA (1, 5). However, the mechanisms underlying UA-induced neuroprotection are still not completely understood. To date, the mechanisms known to be associated with UA actions following cerebral I/R involve suppression of both reactive oxygen species (ROS) accumulation and lipid peroxidation in the brain (39). Nevertheless, the potential impact of UA effects on the cerebral vasculature after stroke has not been investigated.

Large cerebral arteries, like the middle cerebral artery (MCA), have a strong contribution to total cerebrovascular resistance (10). CBF is tightly controlled by myogenic mechanisms to maintain cerebral perfusion (20). A decrease in MCA myogenic response has been consistently reported after transient MCA occlusion and may contribute to the impaired brain
autoregulation (22). Structural alterations of cerebral arteries may also participate in the development of brain injury (24). Thus, these changes might affect regional CBF regulation and lead to distal capillary destabilization and organ damage. For instance, hypertension, which is a leading cause of stroke, induces remodeling of cerebral arteries causing larger infarcts (15, 24). Several lines of evidence suggest that transient MCA occlusion in rats induces MCA wall thickening (7, 14, 15). Increased oxidative stress seems to be involved in such arterial remodeling since antioxidant treatment at reperfusion rescues MCA from remodeling and reduces infarct volume (14). After cerebral I/R, the inflammatory response is accompanied by an increase in macrophage infiltration (32). In addition, recent reports showed that perivascular macrophage-mediated inflammation could be involved in hypertensive cerebrovascular remodeling (25, 26). Remarkably, the factors underlying MCA remodeling after transient cerebral ischemia are not fully identified.

The present study aims to explore the mechanisms underlying why hyperemia at reperfusion is associated with a worse brain injury after ischemic stroke and the potential beneficial effects of UA antioxidant treatment. We provide the first evidence that posts ischemic hyperemia is accompanied with a profound vascular oxidative and inflammatory response that contributes to the development of structural alterations in cerebral arteries. Furthermore, we demonstrate that cerebrovascular remodeling is a target of UA treatment, unveiling a potential new mechanism underlying the protective effects of this compound.

MATERIALS AND METHODS

Animals. Seventy-seven adult male Sprague-Dawley rats obtained from Harlan (Barcelona, Spain) were housed under a 12:12-h light-dark cycle, controlled environmental conditions of temperature and humidity, and provided with access to food and water ad libitum. All of the experiments were carried out under the Guidelines established by the Spanish legislation (RD 1201/2005) and according to the Guide for the Care and Use of Laboratory Animals, published by the United States National Institutes of Health (NIH Publication 85-23, revised 1996). Experiments were approved by the Ethics Committee of the Universitat Autònoma de Barcelona and were carried out in compliance with the European legislation.

Experimental cerebral ischemia. The surgical procedure for induction of focal cerebral ischemia was previously described (23). Rats were anesthetized with isoflurane (2.5–3%) vaporized in O2 and N2O humidity, and provided with access to food and water ad libitum. All animals were housed under a 12:12-h light-dark cycle with the European legislation. Experiments were approved by the Ethics Committee of the States National Institutes of Health (NIH Publication 85-23, revised 1985). Experiments were approved by the Ethics Committee of the States National Institutes of Health (NIH Publication 85-23, revised 1985). Experiments were approved by the Ethics Committee of the States National Institutes of Health (NIH Publication 85-23, revised 1985). Experiments were approved by the Ethics Committee of the States National Institutes of Health (NIH Publication 85-23, revised 1985).

Measurement of CBF. Changes in cortical CBF were measured with a laser-Doppler system (Perimed, Järfalla, Sweden), as reported (23). CBF was continuously monitored for 30 min before ischemia, during the ischemia period, and during the first hour after reperfusion. Values of cortical CBF after reperfusion (during the first 15 min) that recovered to their corresponding baseline values (before occlusion) (±20%) were considered normoperfused (nonhyperemic), whereas increases of cortical CBF above 20% of basal values were considered hyperperfused and a sign of reactive hyperemia (23). Subarachnoid hemorrhage (n = 5) or unsuccessful blood flow measurements because of technical surgical problems (n = 6) were used as criteria to exclude animals from the study.

Treatment. One hundred and thirty-five minutes after the onset of ischemia (i.e., after 45 min of reperfusion), rats were treated with either UA (16 mg/kg) or vehicle (Locke’s buffer) intravenously infused during 20 min. The dose used was previously shown to protect against damage induced by transient focal ischemic brain injury (18, 28, 39).

Animals were randomly assigned to sham operation or ischemia. Ischemic animals were divided into two groups depending on whether they developed hyperemia at reperfusion. Finally, sham-operated, nonhyperemic-ischemic, and hyperemic-ischemic groups received either UA or vehicle as follows: sham-operated vehicle (sham + VEH, n = 13); ischemic nonhyperemic vehicle (I/NH + VEH, n = 11); ischemic hyperemic vehicle (I/H + VEH, n = 12); sham-operated treated with UA (sham + UA, n = 5); ischemic nonhyperemic UA (I/NH + UA, n = 8); and ischemic hyperemic UA (I/H + UA, n = 12).

Tissue preparation. The MCA from the right (ipsilateral to ischemia) and left (contralateral to ischemia) hemisphere was dissected under a surgical microscope and kept in cold KHS. The proximal segment of the ipsilateral MCA was immediately used for pressure myography and processed for nuclei distribution microscopio fluorescence studies (15). Distal ipsilateral MCA segments were used for evaluation of O2– production, immunofluorescence, and mRNA levels (14). Coronal brain sections for immunofluorescence studies were processed as described (23). Plasma (500 μl) was collected intracardially just before rats were killed and was kept at −70°C until the day of nitrite level and multiple ELISA studies. A separate group of rats was used for the analysis of UA levels in plasma and brain by high-performance liquid chromatography (HPLC).

Parallel artificial membrane permeation assay for blood-brain barrier. To evaluate the predictive penetration of UA by passive transport to the brain, parallel artificial membrane permeation assay for blood-brain barrier (PAMPA-BBB) was used following the method described by Di et al. (9). The in vitro permeability (P) of 14 commercial drugs through lipid extract of porcine brain membrane together with the test compounds was determined (3 different experiments in triplicate). A linear correlation between experimental and reported (9) permeability of selected commercial drugs using the PAMPA assay was evaluated (y = 1.566x − 1.089; R² = 0.903) to validate the assay. From this equation and taking into account the limits established by Di et al. (9) for BBB permeation, we established the ranges of permeability as compounds of high BBB permeation [central nervous system (CNS) – P < 1.575; compounds of low BBB permeation (CNS–) – P > 1.575 < 5.175; compounds of uncertain BBB permeation (CNS±) – P > 5.175 > 10.220.33.3 on August 15, 2017 http://ajpheart.physiology.org/ Downloaded from http://ajpheart.physiology.org/ by 10.220.33.3 on August 15, 2017] and low BBB permeation (CNS–) – P > 10.220.33.3 on August 15, 2017 http://ajpheart.physiology.org/ Downloaded from http://ajpheart.physiology.org/ by 10.220.33.3 on August 15, 2017}.

Determination of UA levels in plasma and brain. The concentration of UA in plasma and brain tissue was evaluated by HPLC with ultraviolet detection. Blood samples were obtained from vehicle- and UA-treated animals at different time points (ranging from 10 min to 24 h) under isoflurane anesthesia. Animals were anesthetized and perfused through the heart with saline to remove blood from brain vessels. The brain was obtained 10 and 30 min after UA administration. The method used for UA extraction was adapted from a method.
previously described (17). Briefly, plasma (100 µl) and brain tissue (700 mg) were deproteinized with 10% TCA (20 µl plasma/150 µl brain). Samples were sonicated for 20 s and centrifuged (5 min; 12,000 g). Afterwards, 10 µl supernatant were injected into the HPLC system (PerkinElmer, Madrid, Spain) made of a 200 Pump, a 717 plus Auto sampler, and a 2487 Dual λ absorbance detector. A reverse-phase ODS2 (4.6·200 mm, 5-µm particle size; Waters, Barcelona, Spain) was used. The mobile phase was methanol-5 mM ammonium acetate-acetonitrile (1:96:3 vol/vol/vol), which was run with an isocratic regular low flow rate of 1.2 ml/min, and the wavelength ultraviolet detector was set at 292 nm. Quantification was performed by external calibration. The UA peak in plasma and brain was confirmed by mass spectrometry.

Nitrite levels. NO production was determined by measuring the plasma nitrite contents with the Griess reagent (11). The absorbance at 540 nm was measured and the nitrite concentration was determined by using a calibration curve of standard sodium nitrite concentrations vs. absorbance.

Pressure myography. The structural, mechanical, and myogenic properties of the MCA were studied with a pressure myograph (Danish Myo Tech model P100; J.P. Trading, Aarhus, Denmark), as described previously (14, 15). In brief, the vessel was placed on two glass microcannulas and secured with surgical nylon suture. Intraluminal pressure was reduced to 3 mmHg, and a pressure-diameter curve (3–120 mmHg) was obtained in gassed KHS (37°C). Internal and external diameters (Dint, Dext) were measured for 3 min at each intraluminal pressure. The artery was then set to 70 mmHg and allowed to equilibrate for 30 min at 37°C in gassed calcium-free KHS (0 Ca2+: omitting calcium and adding 10 mM EGTA). A second pressure-diameter curve was obtained in 0 Ca2+ KHS, and Dint and Dext were measured. Structural, mechanical, and myogenic parameters were analyzed as previously described (14, 15).

Measurement of O2•− production. The oxidative fluorescent dye dihydroethidium was used to evaluate production of MCA O2•− in situ, as described previously (14). The specificity of the signal for O2•− was evaluated by incubation with the O2•− scavenger MnII-I-tetakis[1-methyl-4-pyridyl]porphyrin (0.1434 mg/ml, 30 min, 37°C) (Sigma-Aldrich). Under the latter condition, no hydroethidine fluorescence was observed in the tissue in any experimental situation. Quantitative analysis of HE fluorescence was performed with MetaMorph Image Analysis software (Molecular Devices, Sunnyvale, CA), as reported (14, 23).

Immunofluorescence. Frozen transverse sections (14 µm thick) of MCA or coronal brain sections (50 µm thick) were incubated (1 h) with a mouse monoclonal antibody against ENOS (1:100; BD Biosciences, Franklin Lakes, NJ) and cluster of differentiation 68 (CD68, 1:75; AbD Serotec, Kidlington, Oxford, UK); a rabbit polyclonal antibody against interleukin (IL)-18 (1:50; Santa Cruz Biotechnology, Santa Cruz, CA); nitrotyrosine (1:100; Merck Millipore, Billerica, MA); iNOS (1:50; Thermo Scientific, Rockford, IL); and nNOS (1:100; Life Technologies, Alcobendas, Spain); a rabbit monoclonal antibody against phosphorylated extracellular signal-regulated kinase 1/2 (pERK1/2, 1:100; Cell Signaling Technology, Danvers, MA); or a goat polyclonal antibody against vascular cell adhesion molecule-1 (VCAM-1; 1:50, Santa Cruz Biotechnology). After being washed, sections were incubated (45 min) with the secondary antibodies (1:200), a donkey anti-mouse, anti-rabbit, or anti-goat IgG conjugated to Cyanine 3 (Jackson ImmunoResearch Laboratories, West Grove, PA) or Alexa Fluor 568 (Life Technologies) at 37°C. Sections were processed for immunofluorescence staining essentially as previously described (14, 23). The specificity of the immunostaining was verified by omission of the primary antibody and processed as above, which abolished the fluorescence signal. Quantification of CD68 positive cells (CD68+) was performed in a systematic manner, and the count average per ring was calculated for each rat. Quantitative analysis of fluorescence was performed with MetaMorph Image Analysis software (Molecular Devices) as reported (14). In brain, a similar subcortical area from the ipsilateral hemisphere was selected for each experimental condition (coinciding with the infarcted area in ischemic groups), and the complete image field fluorescence (750 × 750 µm) was analyzed. The results were expressed as arbitrary units.

Nuclei distribution by confocal microscopy. Pressure (70 mmHg)-fixed intact MCA was stained with the nuclear dye Hoechst 33342 (10 µg/ml) for 30 min (15). After washing was completed, arteries were mounted on slides with a well made of silicon spacers to avoid artery deformation. They were visualized with a Leica TCS SP2 (Heidelberg, Germany) confocal system. Stacks of serial optical slices (0.5 µm thick) were captured from the adventitia to the lumen of each artery. The different MCA layers stained with Hoechst 33342 were clearly distinguished with confocal microscopy according to the shape and/or orientation of the cell nuclei (2). At least, two stacks of images from several regions were captured in each arterial segment. MetaMorph Image Analysis software (Molecular Devices) was used for quantification. The nuclei number was counted in the z-axis, as previously described (15).

Multiple ELISA. Plasma samples were prepared for analysis in a 96-well plate using a custom 27-cytokine Milliplex MAP Rat Cytokine/Chemokine Magnetic Bead Panel (RECYMAG66K27PMX; Millipore) following the kit-specific protocols. Analytes were quantified using a Magpx analytical test instrument that uses xMAP technology (Luminex, Austin, TX) and xPONENT 4.2 software (Luminex).

Quantitative real-time PCR. mRNA expression was quantified by Syber green-based quantitative real-time PCR (qRT-PCR) as previously described (21). The expression of mRNA for GAPDH of 18S ribosomal RNA was used as an internal control. qRT-PCR reactions were set following the manufacturer’s conditions. Ct values obtained for each gene were referenced to GAPDH 18S (ΔΔCt) and converted to the linear form using the term 2−ΔΔCt as a value directly proportional to the copy number of cDNA and initial quantity of mRNA (21).

Statistics. Results were expressed as means ± SE of the number (n) of rats indicated in the legends for Figs. 1–9. The difference between nonhyperemic or hyperemic rats and the effect of UA treatment were assessed by a two-way ANOVA with Bonferroni’s postest to compare groups. Data analysis was carried out using GraphPad Prism version 4 software. A value of P < 0.05 was considered significant.

RESULTS

Body weight, mean arterial blood pressure, and body temperature during surgery did not vary between groups (Table 1). None of the rats died in either group before the end of the study. The incidence of reactive hyperemia was 56%. The reduction of CBF during ischemia was similar in all the groups, and the extent of CBF increase at reperfusion in the hyperemic groups that later received either UA or vehicle was not different (Table 2).

UA treatment is neuroprotective in animals showing reactive hyperemia. Larger infarct volumes in cortical and subcortical regions were observed in rats showing reactive hyperemia at reperfusion compared with those that did not develop hyperemia (Fig. 1A). Single-dose administration of UA at 135 min after the onset of ischemia reduced (P < 0.05) infarct volume in hyperemic, but not in nonhyperemic, rats (Fig. 1A). Likewise, the neurological score was worse (P < 0.001) in hyperemic than in nonhyperemic animals (Fig. 1B). Treatment with UA ameliorated (P < 0.01) the neuro-
logical score in hyperemic rats without modifying it in nonhyperemic rats (Fig. 1B).

**MCA structural alterations are associated with reactive hyperemia and are prevented by UA treatment.** Arterial diameters were measured over the pressure range from 3 to 120 mmHg under fully relaxed conditions (0 Ca\(^{2+}\)-KHS), and the influence of hyperemia and in vivo UA treatment on the MCA structural properties was studied. Twenty four hours following I/R, the MCA from rats not manifesting reactive hyperemia (nonhyperemic) did not display alterations in external and lumen diameters compared with the MCA of sham-operated rats (Fig. 2, A and B). Conversely, hyperemia was associated with enlarged (P < 0.05) external diameters compared with sham-operated rats (Fig. 2A). Administration of UA did not significantly alter external diameters but caused a lumen diameter increase (P < 0.05) in hyperemic rats and a trend to increase (P = 0.06) in nonhyperemic rats compared with the sham group (Fig. 2, A and B). After I/R, the MCA wall of nonhyperemic rats was not structurally different from that of sham-operated rats (Fig. 2, C and D). In contrast, enlarged wall thickness (Fig. 2C) and cross-sectional area (Fig. 2D), but not wall/lumen (results not shown), were found in hyperemic rats compared with the sham group. Of note, the vehicle (Locke’s buffer) had no effect on MCA structure, since nontreated hyperemic rats displayed the same remodeling observed in hyperemic rats that received the vehicle (data not shown). Notably, UA treatment prevented all hyperemia-induced MCA structural alterations and did not affect MCA structure in sham rats (Fig. 2, C and D).

Analysis of the passive mechanical properties showed that hyperemia decreased wall stress (P < 0.05), and UA treatment prevented this effect (Fig. 3A). The stress-strain relationship (Fig. 3B) and the β-values of the stress-strain relationship were similar irrespective of I/R (sham + VEH: 6.9 ± 0.3, n = 13; I/NH + VEH: 6.7 ± 0.2, n = 11; I/H + VEH: 7.5 ± 0.5, n = 12) and treatment (sham + UA: 6.5 ± 0.1, n = 5; I/NH + UA: 5.8 ± 0.4, n = 8; I/H + UA: 6.5 ± 0.3, n = 12), indicating that the vessel stiffness was not significantly altered by I/R or treatment.

**Ischemia-induced MCA myogenic alterations are not related to reactive hyperemia and are unaffected by UA treatment.** Lumen diameter in active conditions (2.5 mM Ca\(^{2+}\)-KHS) was significantly enlarged (P < 0.05) over the pressure range after I/R, irrespective of the presence or absence of hyperemia, and UA did not modify it (Fig. 3C). Internal diameter reductions in active relative to passive (0 Ca\(^{2+}\)-KHS) conditions reveal the extent of the constrictor tone and reflect the myogenic response as a function of pressure (Fig. 3D). Ischemia, regardless of hyperemia, decreased (P < 0.05) the myogenic response, and UA was not able to prevent this response (Fig. 3D). However, analysis of slopes of the myogenic response-pressure curves (myogenic reactivity) showed that this parameter was not modified either by I/R (sham + VEH: 0.05 ± 0.05, n = 13; I/NH + VEH: −0.01 ± 0.03, n = 11; I/H + VEH: 0.05 ± 0.04, n = 12) or treatment (sham + UA: 0.02 ± 0.06, n = 5; I/NH + UA: 0.01 ± 0.05, n = 8; I/H + UA: 0.01 ± 0.03, n = 12).

**UA suppresses the hyperemia-induced increase in both adventitial volume and AC proliferation.** Nuclei distribution measurements by confocal microscopy from intact and pressurized MCA were 8; I/H

**Table 1. Body weight and physiological parameters at different time points during anesthesia and surgery**

<table>
<thead>
<tr>
<th></th>
<th>I/NH</th>
<th>I/H</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body wt, g</td>
<td>275.90 ± 5.75</td>
<td>264.86 ± 3.96</td>
</tr>
<tr>
<td>Mean arterial blood pressure, mmHg</td>
<td>93.64 ± 13.1</td>
<td>91.86 ± 1.57</td>
</tr>
<tr>
<td>Before ischemia</td>
<td>93.50 ± 1.11</td>
<td>90.57 ± 1.36</td>
</tr>
<tr>
<td>Immediately after reperfusion</td>
<td>91.83 ± 10.9</td>
<td>90.57 ± 1.36</td>
</tr>
<tr>
<td>Body temperature, °C</td>
<td>37.24 ± 0.13</td>
<td>36.85 ± 0.21</td>
</tr>
<tr>
<td>Before ischemia</td>
<td>37.46 ± 0.15</td>
<td>37.26 ± 0.14</td>
</tr>
<tr>
<td>During ischemia (60 min)</td>
<td>37.40 ± 0.12</td>
<td>36.80 ± 0.13</td>
</tr>
</tbody>
</table>

Results are means ± SE from ischemic/nonhyperemic (I/NH; vehicle: n = 11; uric acid: n = 8) and ischemic/hyperemic (I/H; vehicle: n = 12; uric acid: n = 12) rats.

**Table 2. Percentage changes in cortical CBF during ischemia (90 min) and reperfusion (first 15 min) with respect to basal values**

<table>
<thead>
<tr>
<th></th>
<th>I/NH</th>
<th>I/H</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basal CBF, %</td>
<td>Vehicle Uric acid</td>
<td>Vehicle Uric acid</td>
</tr>
<tr>
<td>Ischemia</td>
<td>46.2 ± 3.7</td>
<td>44.7 ± 3.9</td>
</tr>
<tr>
<td>Reperfusion</td>
<td>88.1 ± 6.2</td>
<td>93.1 ± 2.2</td>
</tr>
</tbody>
</table>

Results are means ± SE from I/NH (vehicle: n = 11; uric acid: n = 8) and I/H (vehicle: n = 12; uric acid: n = 12) rats. CBF, cerebral blood flow.

**Increased cerebrovascular oxidative stress is reduced by UA treatment.** We evaluated HE fluorescence along the arterial wall to assess for \(\text{O}_2^−\) production. HE fluorescence along the ipsilateral MCA wall was increased (P < 0.05) in both non-
hyperemic and hyperemic rats compared with sham-operated rats (Fig. 5A). Conversely, the contralateral MCA did not display elevated HE fluorescence after I/R (results not shown). UA treatment slightly diminished the enhanced HE fluorescence in nonhyperemic rats and reduced ($P < 0.001$) it in hyperemic rats (Fig. 5A). Quantitative analysis of mRNA levels of NAD(P)H oxidase subunits (major source of vascular $O_2^-$) showed augmented ($P < 0.05$) gp91phox and p22phox mRNA expression in hyperemic compared with sham-operated rats, and this effect was attenuated ($P < 0.05$) by UA (Fig. 5A). However, UA treatment increased p22phox mRNA levels in nonhyperemic rats.

Hyperemia is associated with enhanced protein nitrotyrosination, and UA reduces this effect. The reaction of $O_2^-$ and NO can lead to ONOO$^-$ formation, which can induce irreversible protein nitrotyrosination. Only the MCA from hyperemic rats showed an increase ($P < 0.05$) in nitrotyrosine immunofluorescence vs. that of sham-operated rats, and this effect was particularly prominent in the adventitia (Fig. 5B). Similarly, only hyperemic rats showed increased ($P < 0.01$) nitrotyrosine fluorescence in brain tissue (Fig. 6). UA treatment reduced ($P < 0.05$) nitrotyrosine immunofluorescence in both the MCA and the brain tissue of hyperemic rats (Figs. 5B and 6).

Expression of eNOS, iNOS, and nNOS in the MCA, as assessed by immunofluorescence, was unaltered by I/R compared with sham operation (results not shown). However, plasma nitrite levels ($\mu$mol/l) were higher ($P < 0.05$) in hyperemic than in sham-operated rats (sham + VEH: 11.62 ± 0.36, $n = 6$; I/NH + VEH: 11.81 ± 0.97, $n = 7$; I/H + VEH: 13.77 ± 0.68, $n = 5$) and were reduced ($P < 0.05$) by UA treatment (sham + UA: 12.25 ± 0.36, $n = 4$; I/NH + UA: 12.10 ± 0.72, $n = 6$; I/H + UA: 10.87 ± 0.74, $n = 7$).

Fig. 1. Beneficial effect of uric acid after ischemia (90 min)-reperfusion (24 h). Rats received the vehicle or uric acid at 135 min after the onset of ischemia. A: representative images of coronal brain sections stained with 2,3,5-triphenyltetrazolium chloride and quantification (bottom) of infarct volume. B: effects of uric acid on neurological score. I/NH, ischemic/nonhyperemic; I/H, ischemic/hyperemic. Results are means ± SE from I/NH (vehicle: $n = 11$; uric acid: $n = 8$) and I/H (vehicle: $n = 12$; uric acid: $n = 12$) rats. *$P < 0.05$, **$P < 0.01$, and ***$P < 0.001$ by 2-way ANOVA.
Elevated levels of circulating IL-1β and IL-18 are a signature of hyperemia and are reduced by UA treatment. To identify potential specific pathways responsible for vascular remodeling in hyperemic animals, we first compared cytokine/chemokine profiling in plasma of sham-operated and I/R rats at 24 h after reperfusion. Among 27 cytokines/chemokines, IL-1β (Fig. 7A) and IL-18 (Fig. 7B) were the only cytokines showing a statistically significant increased concentration in hyperemic compared with sham-operated rats, whereas they were unchanged in nonhyperemic rats. UA treatment normalized hyperemia-induced increases in both IL-1β and IL-18 circulating levels.

Hyperemia is linked to increased monocyte/macrophage recruitment irrespective of UA treatment. Although we did not detect significant changes in VCAM-1 mRNA expression in the MCA 24 h after I/R, VCAM-1 protein expression along the MCA wall increased, predominantly in the adventitia, regardless of hyperemia or UA treatment (Fig. 8A). CD68+ cells were detected in the endothelium and adventitia of the MCA, although they were especially abundant in the latter (Fig. 8B). Hyperemic rats showed an increased CD68+ cell count in the MCA wall that was not modified by UA treatment (Fig. 8B).

MCA IL-18 levels increase after hyperemia and are reduced by UA treatment. Local IL-18 protein expression in the MCA wall (Fig. 8B) was increased ($P < 0.01$) in hyperemic animals, particularly in the endothelium and adventitia. This effect was prevented by UA treatment ($P < 0.05$). Quantitative analysis of IL-18 mRNA levels showed that hyperemia was associated with an increase ($P < 0.05$) in IL-18 mRNA expression in the MCA that again was reduced by UA. Of note, IL-18 mRNA levels were diminished ($P < 0.05$) in nonhyperemic animals compared with sham-operated animals, and increased ($P < 0.05$) after UA treatment. Neither the endogenous neutralizer of IL-18, IL-18-binding protein, nor IL-1β mRNA levels were significantly altered by hyperemia or UA (results not shown).

UA does not penetrate to the brain parenchyma. Table 3 shows permeability results from different commercial compounds and UA using the PAMPA-BBB assay. The assay showed that problem compounds displayed similar experimental permeability values as those reported in the literature, and some of them manifested positive predictive penetration into the CNS. However, UA permeability was poor, which suggests that it does not cross the BBB by passive transport. Plasma and brain UA levels are shown in Fig. 9.
In either plasma (Fig. 9B) or brain (Fig. 9C), levels of endogenous UA were similar in both sham and ischemic rats. UA plasma levels increased 10 min after intravenous UA administration and returned to baseline from 10 min onwards (Fig. 9B). In contrast, UA levels in brain tissue were unaffected by UA infusion (Fig. 9C).

**DISCUSSION**

UA is a potent endogenous antioxidant with encouraging protective effects in ischemic stroke after exogenous administration (5, 18, 28, 39). To date, only one study reported reduction in infarct volume and improved neurological scores after UA treatment administered in a clinically relevant time-frame (180 min after MCA occlusion) (39). In previous studies, development of hyperemia at reperfusion following an episode of brain ischemia was associated with larger infarcts and worse neurological deficits (23). In the present study, we also found that hyperemic rats show larger infarctions and document that UA, administered 135 min after MCA occlusion, decreases infarct volume and improves the neurological score in rats manifesting hyperemia. Therefore, the results of the current study support that exogenously administered UA is effective in the rats showing signs of reactive hyperemia at reperfusion and further identify the cerebral vasculature as a target of UA protection.

Several reports documented hypertrophy of the MCA after transient MCA occlusion (7, 14, 15), and one study (7) suggested that structural alterations may take place after reperfusion. The results of the present study extend those observations and demonstrate for the first time that only those animals that showed hyperemia at early reperfusion displayed arterial wall hypertrophy, which in turn was associated with larger infarct volumes. Based on those observations, we suggest that MCA wall thickening after I/R can be considered a sign of reperfusion injury. UA prevented the hypertrophic response in the MCA induced by hyperemia, suggesting that protection of cerebrovascular structure is a potential mechanism underlying the beneficial effects of UA. Of note, we found that UA displayed low predictive penetration in the CNS and endogenous brain levels of UA were not modified after UA intravenous infusion, suggesting that the target of this compound could be the brain vasculature.
The reduction of CBF during ischemia was similar in all the groups, indicating that hyperemia was not attributable to a more severe CBF drop during ischemia, in agreement with a previous study (23). However, we cannot exclude that hyperemia might be related to higher reductions of CBF in the core of the infarction during ischemia, since our laser Doppler CBF measurement was taken from a superficial cortical area. Previous studies have proposed that hyperemia is linked to an increase in NO production (12, 13). In the present study we did not find changes in MCA NOS protein expression among groups. However, we cannot exclude an increase in MCA NOS activity in hyperemic animals, since circulating nitrite levels were higher in hyperemic rats, suggesting a surge of NO production. In addition to producing relaxation, NO exerts its protective action by scavenging $O_2^-$ (193x76). However, the product of this reaction yields the highly reactive molecule ONOO $^-$ (30x65) that generates protein oxidation and nitrotyrosination (4). The marked protein nitrotyrosination along the MCA wall detected in hyperemic rats extends our previous findings of exacerbated brain protein nitrotyrosination in hyperemic animals (23) and suggests that major nitrotyrosination of the MCA after I/R (22) is associated with reactive hyperemia.

A decrease in the myogenic response is considered an important factor involved in the functional dysregulation of CBF after I/R (22). Previous studies reported a threshold of MCA occlusion for myogenic responses in the rat MCA (6). Consistently, here we show that myogenic alterations do not depend on the degree of blood flow increase at early reperfusion, since both nonhyperemic and hyperemic rats displayed similar myogenic response impairment compared with sham-operated rats. It has been proposed that one of the mechanisms associated with loss of MCA myogenic response is the ONOO $^-$-induced nitrotyrosination and subsequent loss of filamentous actin (8, 19, 22). In our study, the myogenic response...
was impaired in the MCA regardless of the status of protein nitrotyrosination 24 h after I/R, and UA treatment reduced protein nitrotyrosination without restoring the myogenic response in hyperemic rats. However, the myogenic tone of the MCA might suffer a long-lasting or irreversible impairment due to an early production of ONOO⁻ as already suggested (14), which might not be restored by treatments administered later than 2 h after the onset of ischemia. Accordingly, a recent study demonstrated successful recovery of the myogenic response by ONOO⁻ scavenging at reperfusion after shorter periods of ischemia (8).

Improving brain perfusion is essential to prevent neuronal death after ischemic stroke. UA infusion was associated with a passive lumen diameter expansion at 24 h. It has been described that nitrotyrosination of UA by ONOO⁻ can form a product that can release NO (30). Even though circulating nitrite levels at 24 h after reperfusion in UA-treated hyperemic rats were low, we cannot exclude that a potential blood flow increase due, at least in part, to a UA-derived nitration/nitrosation product during reperfusion might contribute to the flow (shear stress)-induced outward remodeling (36). It is possible that the UA-induced luminal expansion of the MCA prevents the secondary hypoperfusion described to take place after reactive hyperemia (34).

In response to stress stimuli, such as overdistension or hypoxia, vascular adventitial cells (ACs) exhibit, among others, increases in adhesion proteins, secretion of chemokines and cytokines, and cell proliferation (31). Our group previously reported an increase in MCA AC number (AC hyperplasia) in rats after I/R, contributing to explain the increased external

---

**Fig. 5.** Influence of uric acid treatment on oxidative stress and protein nitrotyrosination induced by ischemia-reperfusion in rat middle cerebral arteries. A: representative photomicrographs and quantification of fluorescence intensity of confocal microscopic artery sections labeled with the oxidative dye dihydroethidium, which produces a red fluorescence when oxidized to ethidium bromide by superoxide anion. Natural autofluorescence of elastin (green) is also shown. Comparative analysis of mRNA levels of the NAD(P)H oxidase subunit gp91phox and p22phox is also shown (bottom). mRNA levels are expressed as $2^{-\Delta\Delta C_t}$ using 18S as an internal control. B: representative photomicrographs and quantification of nitrotyrosine immunofluorescence of confocal microscopic artery sections. Immunofluorescence signal (red), natural autofluorescence of elastin (green), and nuclear staining (blue) are shown. HE, hydroethidine; Nitro, nitrotyrosine. Results are means ± SE from sham (vehicle: $n=7–10$; uric acid: $n=4–5$), I/NH (vehicle: $n=6–12$; uric acid: $n=3–5$), and I/H (vehicle: $n=5–8$; uric acid: $n=5–7$) rats. *$P<0.05$, **$P<0.01$, and ***$P<0.001$ by 2-way ANOVA with Bonferroni’s posttest.
diameter and the subsequent wall thickening (15). Here we confirm those results and report that AC hyperplasia is a factor involved in MCA external diameter increase leading to hypertrophic remodeling in hyperemic rats. Vascular adventitia is considered an important source of ROS predominantly via NAD(P)H oxidase (31). Previous studies have suggested a relationship between hypertrophy and generation of free radical species in the rat MCA (3, 14). Although we detected

Fig. 6. Influence of uric acid treatment on rat brain protein nitrotyrosination induced by ischemia-reperfusion. Representative photomicrographs and quantification of nitrotyrosine immunofluorescence of close ups of the region of interest in the brain. Immunofluorescence signal (red) and nuclear staining (blue) are shown. Results are means ± SE from sham (vehicle: n = 3; uric acid: n = 3), I/NH (vehicle: n = 3; uric acid: n = 3), and I/H (vehicle: n = 3; uric acid: n = 3) rats. *P < 0.05 and **P < 0.01 by 2-way ANOVA with Bonferroni’s posttest.

A

B

*P < 0.05 and **P < 0.01 by 2-way ANOVA with Bonferroni’s posttest.

Fig. 7. Influence of uric acid treatment on plasma cytokines (pg/ml) after ischemia-reperfusion. IL, interleukin. Results are means ± SE from sham (vehicle: n = 7; uric acid: n = 3), I/NH (vehicle: n = 7; uric acid: n = 7), and I/H (vehicle: n = 7; uric acid: n = 7) rats. *P < 0.05 and **P < 0.01 by 2-way ANOVA with Bonferroni’s posttest.
similar ischemia-induced increases in O$_2^-$ formation, the MCA from hyperemic rats showed increased NAD(P)H oxidase subunit mRNA levels and augmented protein nitrotyrosination compared with nonhyperemic rats, suggesting that hyperemia is associated with exacerbated oxidative stress. UA antioxidant treatment diminished both oxidative stress and ERK1/2 activation and reduced AC proliferation, indicating a key role of oxidative stress in AC hyperplasia. ROS production by adventitial fibroblasts can promote the recruitment of inflammatory cells (25, 31), which in turn generate more ROS, magnifying the impact of oxidative stress (31). Hyperemia was associated with an increased presence of monocytes/macrophages (CD68$^+$ cells), mainly in the MCA adventitia, suggesting that increased adventitial oxidative stress in hyperemic animals could be involved in adventitial monocyte/macrophage recruitment.

Cerebral I/R triggers an inflammatory response that contributes to exacerbate brain damage. Initiation of the inflammatory response can involve the multiprotein complexes termed “inflammasomes” leading to release of proinflammatory cytokines (37). We detected increased levels of circulating IL-1β and IL-18 at 24 h in hyperemic compared with sham animals that were normalized by UA treatment. IL-18 expression was also increased in the MCA wall of hyperemic rats at 24 h, and this effect was prevented by UA treatment. Therefore, these results relate hyperemia with an oxidative stress-dependent cerebrovascular IL-18 accumulation, pointing to a role of IL-18 in early stage inflammation of the cerebral vasculature.

In summary, we demonstrate for the first time that MCA structural, but not myogenic, alterations observed after I/R are restricted to rats that manifest reactive hyperemia at early reperfusion. The underlying mechanism involves prominent oxidative stress, increased macrophage recruitment, and IL-18 accumulation in the MCA of hyperemic rats. This altered environment might favor AC proliferation contributing to MCA remodeling. We also show that exogenously administered UA exerts a more potent brain protective action in
hyperemic than in nonhyperemic rats, at least, by suppressing hyperemia-related MCA wall oxidative stress, inflammation, and hypertrophy and inducing MCA passive lumen diameter expansion. These results provide new insights into the mechanisms by which this compound exerts its protective actions against I/R-induced brain injury. The current data support the concept that UA exerts short-term vascular protection in young male rats. It will be necessary to validate these findings in female rats and in animals with comorbidities and to examine whether the potential UA benefits are sustained in the long term.

ACKNOWLEDGMENTS

We are grateful to Sofia Romeeva, Cristina Marsili, and Ferran Tarrés for the technical assistance and to the confocal microscopy core from the Universitat Autònoma de Barcelona.

GRANTS

The research was funded by grants from Ministerio de Ciencia e Innovación (SAF2010-19282), Generalitat de Catalunya (2009SGR-890), Laboratorios Almirall (2013), and Instituto Carlos III (FIS PI080176; CP06/00308; Red HERACLES RD12/0042/0006). Y. Onetti is a predoctoral fellow of the Ministerio de Educación y Ciencia.

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the authors.

AUTHOR CONTRIBUTIONS

URIC ACID PROTECTS AGAINST HYPEREMIC VESSEL INJURY


REFERENCES

4. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 87: 1620–1624, 1990.

AJP-Heart Circ Physiol • doi:10.1152/ajpheart.00001.2015 • www.ajpheart.org